Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Common Equity (2022 - 2025)

Historic Common Equity for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $219.0 million.

  • Taysha Gene Therapies' Common Equity rose 14661.76% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.0 million, marking a year-over-year increase of 14661.76%. This contributed to the annual value of $71.5 million for FY2024, which is 455.32% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Common Equity of $219.0 million as of Q3 2025, which was up 14661.76% from $248.7 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Common Equity peaked at $248.7 million during Q2 2025, and registered a low of -$49.1 million during Q3 2023.
  • Moreover, its 4-year median value for Common Equity was $53.8 million (2024), whereas its average is $61.0 million.
  • Within the past 5 years, the most significant YoY rise in Taysha Gene Therapies' Common Equity was 779641.73% (2023), while the steepest drop was 55888.07% (2023).
  • Taysha Gene Therapies' Common Equity (Quarter) stood at $949000.0 in 2022, then skyrocketed by 7796.42% to $74.9 million in 2023, then decreased by 4.55% to $71.5 million in 2024, then soared by 206.17% to $219.0 million in 2025.
  • Its Common Equity was $219.0 million in Q3 2025, compared to $248.7 million in Q2 2025 and $55.1 million in Q1 2025.